This brand name is authorized in Turkey
The drug CLOTINAB contains one active pharmaceutical ingredient (API):
|
1
Abciximab
UNII X85G7936GV - ABCIXIMAB
|
|
Abciximab is the Fab fragment of the chimeric monoclonal antibody 7E3. It is directed against the glycoprotein (GP) IIb/IIIa (αIIbβ3) receptor located on the surface of human platelets. Abciximab inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules to GPIIb/IIIa receptor sites on activated platelets. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| B01AC13 | Abciximab | B Blood and blood forming organs → B01 Antithrombotic agents → B01A Antithrombotic agents → B01AC Platelet aggregation inhibitors excl. heparin |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: TR | İlaç ve Tıbbi Cihaz Kurumu | Identifier(s): 8699769950224 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
